LeonaBio, Inc. (LONA) Stock

LeonaBio, Inc. (LONA) is a Healthcare stock trading at $7.36 (as of 2026-07-24), with a market capitalization of $69.14M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

LeonaBio, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies aimed at supporting neuronal health and slowing neurodegeneration. Its pipeline includes ATH-1105 for amyotrophic lateral sclerosis and ATH-1020 for neurodegenerative diseases, each in Phase 1 trials, along with earlier preclinical candidates.

Valuation — source: SEC EDGAR (first-party)
Price$7.36
Market Cap$69.14M
Price / Book1.40
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.2
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderPERCEPTIVE ADVISORS LLC ($19.11M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMark J. Litton
Employees26
CountryUS
IPO Date2020-09-18

Related Companies (Business model: Closed-End Fund; 8 closest by market cap; US-domiciled)

  • Larimar Therapeutics, Inc. (LRMR)
  • Lightbridge Corporation (LTBR)
  • Comstock Inc. (LODE)
  • LENSAR, Inc. (LNSR)
  • LanzaTech Global, Inc. (LNZA)
  • Laird Superfood, Inc. (LSF)
  • Lipocine Inc. (LPCN)
  • Lisata Therapeutics, Inc. (LSTA)
LONA earnings history · LONA institutional & insider holders · LONA KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-24.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.